Barely Significant
← all phrases

“a nonsignificant trend”

5,407 sentences · 5,407 papers · 7,516 search hits before verification · confirmed specimen

Sighted at

p<0.1

Listed by Hankins (2013) · Otte et al. (2022)

In the literature

Subgroup Analysis No statistically significant interaction was found for the risk of the primary composite outcome in patients with COPD with age (<75 years or ≥75 years; P int =0.330), sex ( P int =0.896), CHA 2 DS 2 ‐VASc score <4 versus ≥4 ( P int =0.654), paroxysmal AF (versus all other AF types; P int =0.334), chronic kidney disease ( P int =0.149), and OAC ( P int =0.691), but a nonsignificant trend for a lower risk was found according to the prescription of BB at baseline ( P int =0.063; Figure 3A ).
In this context, it is worth noting that the study by Köhnlein et al 23 had the highest hypercapnia threshold as an eligibility criterion (PaCO 2 $7 kPa), and also showed a statistically significant survival benefit (and a nonsignificant trend toward fewer hospital admissions).
In the six patients for whom blood samples before and after glucocorticoid treatment were available, there was a nonsignificant trend toward higher diversity, suggesting that the diversity of TCRs in patients with IOI may have been restored to some extent after glucocorticoid treatment, which is consistent with the results reported in the literature above.
A concurrent diagnosis of PMR showed a nonsignificant trend toward reduced ACS risk in three studies. 21 , 23 , 24 Data on clinical presentation or imaging phenotype showed no significant associations with ACS risk. 17 , 18 Importantly, although extracranial GCA may plausibly confer a different (potentially higher) risk of ACS than cranial disease, the included studies did not report subtype (cranial/extracranial/mixed) data in a sufficiently consistent manner to allow subtype-specific analyses, and whether ACS risk varies across GCA phenotypes therefore remains unclear.
66 On-label 20 mg showed a nonsignificant trend toward lower risks of stroke, hospitalization for gastrointestinal bleeding or major bleeding, and all-cause death compared with off-label 15 mg. 66 Overall, on-label 20 mg showed significantly better results for the composite clinical outcome compared with off-label 15 mg. 66 On the other hand, an
70 While the WHO-conducted trial showed no benefit in terms of survival in patients with COVID-19, 71 another study showed a shortening in the time to recovery in hospitalized adults and a nonsignificant trend also for improved survival at day 29 from hospitalization. 72 While the discussion regarding its benefit for COVID-19 management is far from being closed, remdesivir is being used in clinical practice in patients with severe forms of the disease.
Pharmacological management of COVID-19 in type 2 diabetes.
J Diabetes Complications · 2021 · PMC8052602